Drugs / LM-305
last change Dec 2025 re-read 2 minutes ago

LM-305

Developed for
plasma cell myeloma
Investigated by
LaNova Medicines Limited

Trials 1 · a red edge is where a trial was stopped

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05647512 Jan 2023 → Dec 2024 plasma cell myeloma LaNova Medicines Limited Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LM-305 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05647512
Route Intravenous “Administered intravenously” NCT05647512